J&J Stock Soars Above $270 as Q2 Sales Hit Record

Johnson & Johnson's stock is trading above $270 per share after the company reported record second-quarter sales and raised its full-year guidance. The diversified healthcare group declared a cash dividend of $1.34 per share, with an ex-dividend date of August 25, 2026, and a payment date set for September 8, 2026.

The company's Q2 2026 sales reached $25.3 billion, a new quarterly record and representing year-over-year revenue growth of 6.6 percent. Adjusted earnings reached $2.90 per share, with the Innovative Medicine segment delivering operational growth of 6.8 percent in the quarter.

Johnson & Johnson's management raised both its current fiscal-year sales and adjusted EPS guidance in connection with the Q2 2026 release, reiterating that the company remains on track to exceed $100 billion in annual revenue in 2026 for the first time in its history.